Poll

POLL: Will you use biosimilars in your ophthalmic practice?

Author(s):

Sheryl Stevenson

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Will you use biosimilars in your ophthalmic practice?

Yes, I plan to use biosimilars in my practice
No, I do not plan to use biosimilars in my practice
Related Videos
Image credit: ©Ophthalmology Times
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Image credit: Mercy Ships
February 4th 2025

Mercy Ships delivers a lifeline for eye health in Africa’s remote communities

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars
February 3rd 2025

CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Gene therapy voretigene neparvovec boosts vision in pediatric IRD patients
February 2nd 2025

Gene therapy voretigene neparvovec boosts vision in pediatric IRD patients

Beacon Therapeutics receives Regenerative Medicine Advanced Therapy designation for laruparetigene zovaparvovec (laru-zova)
February 2nd 2025

Beacon Therapeutics receives Regenerative Medicine Advanced Therapy designation for laruparetigene zovaparvovec (laru-zova)

© 2025 MJH Life Sciences

All rights reserved.